Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2014 04:00 ET | Source: Pluri Inc.

UK's Minister for Universities and Science, David Willetts & His Delegation Visit Pluristem Regarding UK-Israel Cooperation on Regenerative Medicine

HAIFA, Israel, March 26, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that a delegation from...
March 25, 2014 04:00 ET | Source: Pluri Inc.

Pluristem Scientists to Present a Poster on GvHD & Participate in a Panel Discussion at the BIRAX Regenerative Medicine Conference

HAIFA, Israel, March 25, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced its participation in the...
March 12, 2014 04:00 ET | Source: Pluri Inc.

Preclinical Results for Pluristem's PLX-PAD Cells in Tendon Injury Presented at American Academy of Orthopedic Surgeons' Annual Meeting

HAIFA, Israel, March 12, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that Dr. Scott Rodeo of...
March 11, 2014 04:00 ET | Source: Pluri Inc.

Pluristem to Present at Barclays and RegenMed Financial Conferences

HAIFA, Israel, March 11, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that Company executives...
March 07, 2014 10:45 ET | Source: Pluri Inc.

Pluristem CEO Zami Aberman to Present on Cell & Gene Therapy Panel Discussion at BIO-Europe Spring 2014

HAIFA, Israel, March 7, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the Company's Chief...
March 06, 2014 03:00 ET | Source: Pluri Inc.

US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process

HAIFA, Israel, March 6, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that the United States...
February 20, 2014 03:00 ET | Source: Pluri Inc.

Pluristem Submits FDA Orphan Drug Application for Preeclampsia

HAIFA, Israel, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it is submitting its...
February 18, 2014 03:00 ET | Source: Pluri Inc.

Pluristem Receives Key 3D Cell Expansion Patent in Australia

HAIFA, Israel, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new...
February 13, 2014 03:00 ET | Source: Pluri Inc.

Pluristem CEO Zami Aberman to Speak on Panel at 9th Annual Stem Cell Summit on February 18, 2014

HAIFA, Israel, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that its CEO and...
February 11, 2014 03:00 ET | Source: Pluri Inc.

Medical Key Opinion Leaders in Preeclampsia Join Pluristem's Steering Committee

HAIFA, Israel, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has formed a...